SVB Wealth LLC Has $2.65 Million Holdings in Pfizer Inc. $PFE

SVB Wealth LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 20.1% during the first quarter, Holdings Channel.com reports. The institutional investor owned 94,319 shares of the biopharmaceutical company’s stock after selling 23,728 shares during the period. SVB Wealth LLC’s holdings in Pfizer were worth $2,648,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the 3rd quarter worth approximately $16,613,000. Mackenzie Financial Corp raised its stake in Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after acquiring an additional 1,691,773 shares during the period. Penn Davis Mcfarland Inc. lifted its holdings in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Pfizer during the 3rd quarter worth about $81,298,000. 68.36% of the stock is owned by institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer reported that its experimental lung cancer treatment, sigvotatug vedotin, missed the main goal in a late-stage Phase 3 trial, a setback that raises questions about the drug’s commercial prospects and the strength of the company’s oncology pipeline. Article: Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: Investors are also digesting leadership turnover after Pfizer said CFO Dave Denton will step down effective August 15, which adds near-term uncertainty around financial leadership. Article: Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
• Neutral Sentiment: Pfizer said it is not planning a major acquisition in the next couple of years and instead wants to use artificial intelligence to improve operations, signaling a focus on internal efficiency rather than M&A-driven growth. Article: Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Neutral Sentiment: Broader commentary around Pfizer’s valuation, dividend appeal, and obesity-drug strategy may be supporting longer-term investor interest, but these pieces are not likely the main driver of the stock’s move today. Article: Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.07 on Tuesday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company’s 50 day moving average price is $26.18 and its two-hundred day moving average price is $26.33. The firm has a market cap of $142.87 billion, a PE ratio of 19.14 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.